Literature DB >> 32866782

CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.

Xiaoling Shang1, Jia Li2, Hui Wang3, Zhenxiang Li4, Jiamao Lin5, Dawei Chen6, Haiyong Wang7.   

Abstract

BACKGROUND: The aim of this study was to clarify the association between CMTM6 and PD-L1 expression as well as microenvironment in lung squamous carcinoma (LUSC).
MATERIAL AND METHODS: Using Spearman's correlation and Tumor Immune Estimation Resource (TIMER), we analyzed the relationship between CMTM6 and PD-L1 mRNA in LUSC. Immunohistochemistry (IHC) assay was applied to validate the correlation between CMTM6 and PD-L1 protein level in 80 LUSC samples originated from Shandong Provincial Hospital. Then, using The Cancer Genome Atlas (TCGA) database and fisher test, we analyzed the differential mutation genes in high and low CMTM6 expression group. TISIDB was used to explore the distribution of CMTM6 across immune- and molecular-subtypes. TCGA database and Gene Set variation analysis (GSVA) were used to analyze the relationship between CMTM6 and immune genes, immune related pathways. RESULT: Positive correlation between CMTM6 and PD-L1 in mRNA and protein level was found in LUSC patients. More gene mutations were found in CMTM6 high expression group compared with low expression group. Meanwhile, we also found the correlation between CMTM6 expression and molecular subtypes, immune genes, immune related pathways. Furthermore, our result revealed that B cells memory, T cells memory testing, T cells folicular helper, macrophages M0, macrophages M1 and neutrophils varied significantly between patients with CMTM6 high and low expression group. Finally, we found that CMTM6 expression was positively related to CD8 + T cell, macrophage, neutrophil and dendtritic cell (all, P < 0.05) and negatively related to CD4 + T cell (P = 0.018).
CONCLUSION: CMTM6 is positively associated with PD-L1 expression and correlates with infiltration of immune cells in microenvironment of lung squamous carcinoma.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CMTM6; Immune cells infiltration; LUSC; PD-L1

Mesh:

Substances:

Year:  2020        PMID: 32866782     DOI: 10.1016/j.intimp.2020.106864

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

Review 1.  CMTM6, a potential immunotherapy target.

Authors:  Jie Liang; Shaohua Li; Wei Li; Wei Rao; Shuo Xu; Haining Meng; Fengqi Zhu; Dongchang Zhai; Mengli Cui; Dan Xu; Jinzhen Cai; Bei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-16       Impact factor: 4.553

Review 2.  The clinical and prognostic significance of CMTM6/PD-L1 in oncology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani
Journal:  Clin Transl Oncol       Date:  2022-03-12       Impact factor: 3.340

3.  Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.

Authors:  Yanbin Zhao; Minghui Zhang; Haihong Pu; Shengyue Guo; Shuai Zhang; Yan Wang
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

4.  Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity.

Authors:  Hanfeng Wang; Yang Fan; Weihao Chen; Zheng Lv; Shengpan Wu; Yundong Xuan; Chenfeng Wang; Yongliang Lu; Tao Guo; Donglai Shen; Fan Zhang; Qingbo Huang; Yu Gao; Hongzhao Li; Xin Ma; Baojun Wang; Yan Huang; Xu Zhang
Journal:  Oncoimmunology       Date:  2022-01-05       Impact factor: 8.110

5.  The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer.

Authors:  Xiangzheng Liu; Xueqian Shang; Jian Li; Shijie Zhang
Journal:  Front Cell Dev Biol       Date:  2021-08-03

6.  BCL2A1 and CCL18 Are Predictive Biomarkers of Cisplatin Chemotherapy and Immunotherapy in Colon Cancer Patients.

Authors:  Taohua Yue; Xiangzheng Liu; Shuai Zuo; Jing Zhu; Jichang Li; Yucun Liu; Shanwen Chen; Pengyuan Wang
Journal:  Front Cell Dev Biol       Date:  2022-02-21

Review 7.  CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review.

Authors:  Jie Li; Xiaozi Wang; Xiaoning Wang; Yan Liu; Na Zheng; Pengwei Xu; Xianghong Zhang; Liying Xue
Journal:  Cancer Manag Res       Date:  2022-04-26       Impact factor: 3.602

Review 8.  CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.

Authors:  Tong Zhang; Haixiang Yu; Xiangpeng Dai; Xiaoling Zhang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.